At three months, all ADM sheets were incorporated. Meshed ADM showed fewer giant cells and less foreign body reaction, demonstrated fewer inflammatory cells, deeper fibroblasts penetration and more remodeling with mature native porcine collagen.
INTRODUCTION:
Fibrosis can enhance the exacerbation of lymphedema, which becomes obvious in Late Stage II -Stage III lymphedema.
1-2
However, whether the far-infrared radiation thermotherapy(FIRT) can cure lymphedema fibrosis is still lack of research. This research was to investigate the therapeutic effect of FIRT on tissue fibrosis in the treatment of Late Stage II to III lymphedema by evaluating clinical and laboratory evidence.
METHODS:
Patients accepted only FIRT for 4 weeks (5 working days per week) for a total of 20 sessions. The treatment session duration was 2 hours and a stable machine temperature of 42°C was maintained throughout treatments. Clinical evaluation and laboratory evaluation were conducted to assess the enrolled patients before and after FIRT. Clinical outcome measures included circumference of affected extremity, skin elasticity, ultrasound,patients'subjective assessment and quality of life. Laboratory outcome measures included serum and local lymphedema tissue fluid concentrations of fibrosis associated cytokines TGF-β1, IL-1β, IL-4, IL-18 and Caspase-1.
RESULTS:
Between 2015 and 2016, clinical evaluation of 64 patients with Late Stage II to III lymphedema was conducted before and after FIRT. From this group, 12 cases (18.75%) underwent simultaneous laboratory evaluation. Circumferences of affected extremities improved significantly following treatment(p=0.000). Skin elasticity parameters R0, R2, R5, and Q0 for the affected extremity improved significantly following treatment (p=0.001, 0.031, 0.005 and 0.001 respectively). Ultrasound investigation showed reduced fibre and dense material in the affected tissue (increased grey level 6.322 ± 7.624%, p=0.000). Patients reported a subjective improvement of their symptoms: decreased tightness, heaviness, solidity, pain, discomfort and numbness (p=0.000, 0.000, 0.000, 0.000, 0.000 and 0.032 respectively), and improved quality of life (p=0.000). Laboratory results revealed a significant decrease in local tissue fluid concentrations of TGF-β1 (p=0.041) and IL-18 (p=0.049) after course completion.
CONCLUSION:
FIRT provides an effective treatment for lymphedema tissue fibrosis; it reduces the concentration of fibrosis cytokines in local lymphedema tissues. Consequently, this treatment can reduce the density of fibrosed tissue in the affected extremity, increase skin elasticity, significantly improve clinical symptoms and improve the quality of life of patients. 
INTRODUCTION:
Lipedema is a chronic disorder characterized by localized adiposity, typically isolated to the lower extremities (LEs). The interplay between the deposition of fatty tissue associated with lipedema and impairments of lymphatic flow remains unclear. The purpose of this study is to evaluate lymphoscintigraphic findings in patients with a clinical diagnosis of lipedema in order to better characterize their lymphatic flow and whether impairments in flow contribute to the burden of disease.
METHODS:
Patients with a clinical diagnosis of lipedema receiving lymphoscintigraphy between January, 2015 and January, 2017 were included in this study. Patient demographics, clinical characteristics, and lymphoscintigraphic findings were extracted. Kleinhans' transport index (TI) was utilized to assess lymphatic flow in these patients. Scores range from 0 to 45 with higher scores indicating greater impairments in flow and transport indices greater than 9 denoting pathologic lymphatic transport.
RESULTS:
A total of 8 patients (16 LEs) with a clinical diagnosis of lipedema received lymphoscintigraphic evaluation. Mean age was 55.6 and mean BMI was 35.5 kg/m 2 . No patients had a history of cancer diagnosis, lymph node dissection, or radiation. Severity of lipedema was classified as stage 1 in 2 patients (25%), stage 2 in 2 patients (25%), stage 3 in 2 patients (25%), and stage 4 in 2 patients (25%). Visualization of at least 1 inguinal lymph node occurred in all LE and parailliac lymph nodes were visualized in 15 (93.8%) LE. Dermal backflow was observed in 5 (31.3%) LEs. Mean TI was 8.81 (SD + 9.04). Overall, 6 (37.5%) LEs had a pathologic TI index (TI > 9) including 1 LE with stage 1, 2 LEs with stage 2, and 3 LEs with stage 3 lipedema. Mean differences in TI scores between each LE in patients was 5.00 (SD + 5.10) with 4 (50%) patients having differences of 5 or greater between legs.
CONCLUSION:
Preliminary data suggests that a significant number of patients with a clinical diagnosis of lipedema have impaired lymphatic flow. Interestingly, despite the symmetric clinical profile of the disease, half of the patients in this study had notable asymmetric lymphatic flow on lymphoscintography. Understanding the lymphatic component of this disease may help guide surgical treatment. Modern body armor, rapid evacuation, and advanced combat casualty care have improved survival after catastrophic extremity and maxillofacial trauma. Restoration using vascularized composite allotransplantation (VCA) is superior in many cases to conventional reconstruction but requires immunosuppression and long-term outcomes suffer due to chronic rejection (CR). An approach that can improve the functional outcome, reduce immunosuppression load and minimize or eliminate CR would have a substantial impact on VCA and increase the number of war fighters who benefit. To mitigate obligate reperfusion injury and subsequently CR in VCA, we evaluate the efficacy of ex vivo tissue preservation using a novel machine preservation (MP)/hemoglobin oxygen carrier (HBOC) for 17 hours.
Prevention of Ischemic-Reperfusion

METHODS:
A proven porcine myocutaneous heterotopic transplant model was performed. Control flaps (n=24) underwent CSP at 4°C with
